相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Biosimilars: The Need, The Challenge, The Future: The FDA Perspective
Michael S. Epstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
The economic burden of TNF alpha inhibitors and other biologic treatments in Norway
Jan Norum et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2011)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Controlling the cost of innovative cancer therapeutics
Nafees N. Malik
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Review article: infliximab therapy for inflammatory bowel disease - seven years on
P Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial
P Rutgeerts et al.
GASTROENTEROLOGY (2005)
Infliximab in inflammatory bowel disease:: clinical outcome in a population based cohort from Stockholm County
T Ljung et al.
GUT (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Bioequivalence and the immunogenicity of biopharmaceuticals
H Schellekens
NATURE REVIEWS DRUG DISCOVERY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
A critical assessment of new therapies in inflammatory bowel disease
P Rutgeerts
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)